Fennec Pharmaceuticals Inc faces a challenging day on the TSX, with its stock down 2.20%.
Fennec Pharmaceuticals Inc (FRX.TO) saw its stock price drop significantly during the last trading session, closing at CA$12.44. This 2.20% decline raises concerns among investors about what might be driving this downturn.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Fennec Pharmaceuticals Inc
FRX.TO
FRX.TO
Fennec Pharmaceuticals Inc
WealthAwesomeMarket cap
$503.69M
52W high
$15.48
52W low
$7.59
1W change
-5.35%
Beta
1.07
Analyst Price Targets
Based on analyst covering FRX
Wall Street analysts forecast FRX stock price to rise 545.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$93.57
+545.3% Upside
Current Price
C$14.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on FRX's historical volatility
30-Day Vol
51.2%
Annualized
90-Day Vol
86.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$17.33
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$15.39 | C$12.90 – C$18.37 |
| 60 trading days | C$16.33 | C$12.72 – C$20.97 |
| 90 trading days | C$17.33 | C$12.76 – C$23.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Fennec Pharmaceuticals has been active in the market, this recent slide could suggest that investors are feeling cautious due to ongoing financial challenges.
Fennec Pharmaceuticals Inc's stock declines by 2.20%
With a market cap of CA$441.86 million, this recent performance signals a need for strategic reassessment to rebuild investor confidence.
Bull case
Investors might find potential in Fennec's long-term strategies, especially with recent leadership changes aimed at boosting growth in its oncology product, PEDMARK®.
Bear case
The current stock drop highlights worries about the company's financial health, shown by its negative profit margin and lack of dividends, which could discourage potential investors.
Market Reaction
Fennec Pharmaceuticals' stock decline surprised some investors, particularly given the company's recent efforts to strengthen its leadership team. However, the negative profit margin and absence of a dividend may have raised concerns for those assessing the stock's viability. Investors should keep a close eye on the company's financial disclosures and market positioning.
Company Performance Overview
With a market capitalization of CA$441.86 million, Fennec Pharmaceuticals is navigating a competitive landscape in the biopharmaceutical sector. The stock's recent performance highlights potential vulnerabilities, especially as the company aims to expand its market presence with products like PEDMARK®. Investors should weigh these factors when evaluating the stock's future potential. For more insights, check out our detailed analysis on Fennec Pharmaceuticals Inc.
Advertisement
